Human Health Innovation
Digital innovation: “Our digital pipeline is only growing”
BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.
Search
70 Result(s)
September 28, 2016
BOEHRINGER INGELHEIM BOOSTS IMMUNE-ONCOLOGY PIPELINE THROUGH COLLABORATION WITH VIRATHERAPEUTICS
May 14, 2020
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
December 10, 2020
Boehringer Ingelheim to acquire NBE-Therapeutics
August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Science Stories
Preserving and Restoring Vision
Pioneering research on therapies for people living with DMI
Animal Health Innovation
Interview with Eric Haaksma, Head of Animal Health Global Innovation
On evolution of R&D in the coming years, human and animal health synergies, and so much more...
Retinal Diseases
Our Vision for Retinal Health
Visual impairment and blindness have a profound and devastating impact on the lives of the affected person, their families and society as a whole.
Science Stories
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
Carine Boustany, SVP, Site Head Discovery Research US discusses Boehringer Ingelheim’s research approach in fibrosis.
Human Health Partnering Interests
Retinal Health
Retinal Diseases
A Clear Vision
As experts in Retinal Health, we aim to transform the retinal health landscape by developing novel treatments and technologies, especially where nothing currently exists.
Human Health Partnering Interests
Oncology and Cancer Immunology Partnering Interests
Human Health Partnering Interests
Immunology
Sustainable Development - Our Commitment
Our Partnering Culture
We embrace the power of partnerships and alliances to find even more breakthrough therapies that can change lives.
Sustainable Development
Strategic Pillar: Availability
Across Cancer Types
How scientific congresses drive patient benefit
What is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical representatives? Let’s shed some light.
Borderline Personality Disorder
Championing Novel Science
Dr. Vikas Mohan Sharma discusses the unmet need in Borderline Personality Disorder treatment and Boehringer Ingelheim’s role in research
Cancer
Why cancer care is personal for us
Find out more about Boehringer Ingelheim’s generational commitment to transforming cancer care.
August 03, 2021
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development
October 16, 2019
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
August 12, 2019
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
September 13, 2018